argenx SE (ARGX) Won Its Phase 3 Myositis Trial. How Much Does the Subgroup Miss Matter?

Reported by Yahoo Finance · Published 22 Aug 2026, 8:53 AM MYT (1 d ago)

Summary

Source & full coverage: this summary is aggregated from Yahoo Finance, the original publisher. Read the complete report for full context, data and quotes.

Read the original report at Yahoo Finance →

Most Recent

Alibaba proposes US$10bil share placement to fund global AI drive 1 hr ago Trump says Canada wants 'benefits' of being US state as Carney says countries in trade war 3 hr ago NexG welcomes govt decision not to acquire Datasonic 3 hr ago Mayors to get powers to overrule local councils on planning decisions 5 hr ago Cyber attack shut down small power plant 6 hr ago Could Canada fully supply the U.S. with aluminium? 8 hr ago

EconPulse

Markets. Economy. Malaysia & The World.

Independent economic news aggregation for Malaysia, Asia and global markets, updated throughout the day.

Company

About Us Editorial Standards & Corrections Privacy Policy

Work With Us

Submit a Press Release Partnerships & Advertising Contact Us RSS Feed

Contact

editor@econpulse.my

Editorial & newsroom enquiries answered within 1–2 business days.

argenx SE (ARGX) Won Its Phase 3 Myositis Trial. How Much Does the Subgroup Miss Matter?

Summary

More in Markets

Has Wall Street Entered the "Show Me" Phase of AI?

GE Vernova's Backlog Is Bigger Than Some Countries' GDP. Here's What's Actually Inside the $176 Billion.

91-year-old supermarket chain closes stores, lays off employees

Her Advisor Said Wait Until 70. At 66, She Chose Time to Enjoy Social Security Over an 8%-a-Year Raise.

The 30-Year Treasury Now Out-Yields Dividend Stocks by 2.2 Points. History Says What Followed the Last Time.

Top analyst sees trouble looming for SpaceX stock